TAS-120

Delivery:
oral
Indication:
solid tumors
Locations:
US EU JP

TAS-120 is the first covalent FGFR inhibitor that will be tested in clinic and has the potential to selectively inhibit tumor growth of cancer cells with FGFR abnormalities.

Link to clinicaltrials.gov